A randomized double-blind trial of comparative efficacy and safety of Avonex and CinnoVex for treatment of relapsing-remitting multiple sclerosis

Hossein Pakdaman, Mehdi Abbasi, Koroush Gharagozli, Farzad Ashrafi, Hosein Delavar Kasmaei, Ali Amini Harandi
  • Neurological Sciences, August 2018, Springer Science + Business Media
  • DOI: 10.1007/s10072-018-3550-8

Comparison of Two different interferon-beta formulations for treatment of RRMS

What is it about?

In this study, during 4.5-year follow-up, we compared efficacy and safety of two different formulations of interferon- beta namely AVONEX and CINNOVEX for treatment of RRMS.

Why is it important?

In developing countries, the cost of treatment is of paramount importance for both patients and physicians. this study highlighted that the efficacy and safety of nationally produced interferon -beta (CINNOVEX) are not different from that of its well-known parallel product (AVONEX).

Perspectives

Dr Mehdi Abbasi
Shahid Beheshti University of Medical Sciences

this article highlights the fact that nationally produced interferon-beta (CINNOVEX) is superior to AVONEX with respect to its cost for Iranian patients with RRMS

Read Publication

http://dx.doi.org/10.1007/s10072-018-3550-8

The following have contributed to this page: Dr Mehdi Abbasi